- Home
- STRW vs TLSI Comparison
STRW vs TLSI Comparison
Compare STRW & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- TLSI
- Stock Information
- Founded
- STRW 2015
- TLSI 2010
- Country
- STRW United States
- TLSI United States
- Employees
- STRW N/A
- TLSI N/A
- Industry
- STRW Real Estate Investment Trusts
- TLSI Medical Specialities
- Sector
- STRW Real Estate
- TLSI Health Care
- Exchange
- STRW Nasdaq
- TLSI Nasdaq
- Market Cap
- STRW 154.1M
- TLSI 150.0M
- IPO Year
- STRW N/A
- TLSI N/A
- Fundamental
- Price
- STRW $11.75
- TLSI $4.43
- Analyst Decision
- STRW Strong Buy
- TLSI Strong Buy
- Analyst Count
- STRW 4
- TLSI 5
- Target Price
- STRW $12.72
- TLSI $10.90
- AVG Volume (30 Days)
- STRW 25.5K
- TLSI 107.9K
- Earning Date
- STRW 11-10-2025
- TLSI 11-13-2025
- Dividend Yield
- STRW 4.73%
- TLSI N/A
- EPS Growth
- STRW 27.31
- TLSI N/A
- EPS
- STRW 0.59
- TLSI N/A
- Revenue
- STRW $135,145,000.00
- TLSI $35,990,000.00
- Revenue This Year
- STRW $33.39
- TLSI $56.79
- Revenue Next Year
- STRW $5.21
- TLSI $54.15
- P/E Ratio
- STRW $20.01
- TLSI N/A
- Revenue Growth
- STRW 24.72
- TLSI 45.50
- 52 Week Low
- STRW $8.70
- TLSI $3.42
- 52 Week High
- STRW $12.90
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- STRW 54.40
- TLSI 41.24
- Support Level
- STRW $11.40
- TLSI $4.80
- Resistance Level
- STRW $12.17
- TLSI $5.10
- Average True Range (ATR)
- STRW 0.41
- TLSI 0.28
- MACD
- STRW -0.06
- TLSI -0.06
- Stochastic Oscillator
- STRW 47.37
- TLSI 2.17
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.